Literature DB >> 16816455

First cluster of C. difficile toxinotype III, PCR-ribotype 027 associated disease in France: preliminary report.

M Tachon1, C Cattoen, K Blanckaert, I Poujol, A Carbonne, F Barbut, J C Petit, B Coignard.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16816455     DOI: 10.2807/esw.11.18.02951-en

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


× No keyword cloud information.
  6 in total

1.  Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1.

Authors:  Thomas Akerlund; Ingela Persson; Magnus Unemo; Torbjörn Norén; Bo Svenungsson; Marlene Wullt; Lars G Burman
Journal:  J Clin Microbiol       Date:  2008-02-20       Impact factor: 5.948

2.  Impact of ribotype 027 on Clostridium difficile infection in a geriatric department.

Authors:  G Mascart; M Delmée; J Van Broeck; E Cytryn; R Karmali; S Cherifi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-05       Impact factor: 3.267

Review 3.  Hypervirulent strains of Clostridium difficile.

Authors:  Barry Cookson
Journal:  Postgrad Med J       Date:  2007-05       Impact factor: 2.401

4.  Genetic relatedness of Clostridium difficile isolates from various origins determined by triple-locus sequence analysis based on toxin regulatory genes tcdC, tcdR, and cdtR.

Authors:  Philippe J M Bouvet; Michel R Popoff
Journal:  J Clin Microbiol       Date:  2008-10-01       Impact factor: 5.948

5.  [Emerging multidrug-resistant microorganisms among travelers returning to France and persons repatriated from foreign hospitals].

Authors:  Didier Lepelletier; Antoine Andremont; Patrick Choutet
Journal:  Bull Acad Natl Med       Date:  2009-11       Impact factor: 0.144

Review 6.  Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread.

Authors:  Archie C A Clements; Ricardo J Soares Magalhães; Andrew J Tatem; David L Paterson; Thomas V Riley
Journal:  Lancet Infect Dis       Date:  2010-06       Impact factor: 25.071

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.